The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
Brief Report
PreviousPrevious
Volume 332:642-645 March 9, 1995 Number 10
NextNext

Treatment of Severe Colchicine Overdose with Colchicine-Specific Fab Fragments
Frédéric J. Baud, M.D., Alain Sabouraud, Pharm.D., Ph.D., Eric Vicaut, Ph.D., Pierre Taboulet, M.D., Jean Lang, M.D., Ph.D., Chantal Bismuth, M.D., Jean Marc Rouzioux, M.D., Ph.D., and Jean-Michel Scherrmann, Pharm.D., Ph.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
The use of colchicine is limited by its toxicity,1 and colchicine overdose is associated with a high mortality rate. Patients with early hemodynamic collapse due to colchicine overdose have particularly poor prognoses,2,3 and there has been no effective treatment for this complication of severe colchicine intoxication.4

Colchicine binds reversibly to tubulin,5 and colchicine-specific antibodies have been shown to restore the activity of tubulin in vitro.6,7 Colchicine-specific active immunization in rabbits and passive immunization in mice with substoichiometric doses of goat colchicine-specific antibodies and their Fab fragments have been shown to prevent or reverse acute colchicine poisoning.8,9,10,11 These findings suggested that . . . [Full Text of this Article]

Case Report

Methods

Preparation of Colchicine-Specific Fab Fragments

Treatment of the Patient with Colchicine-Specific Fab Fragments

Hemodynamic Studies

Results

Discussion


Source Information

From Réanimation Toxicologique (F.J.B., P.T., C.B.), INSERM Unité 26 (A.S., J.-M.S.), and the Département de Biophysique (E.V.), Hôpital Fernand Widal, Paris; and Pasteur-Mérieux Sérums et Vaccins, Lyon, France (J.L., J.M.R.).

Address reprint requests to Dr. Baud at Réanimation Toxicologique, Hôpital Fernand Widal, Université Paris 7, 200 rue du Faubourg Saint-Denis, 75010 Paris, France.

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.